Bepirovirsen, an investigational antisense oligonucleotide, led to sustained virologic response and a sustained decrease in hepatitis B virus (HBV) DNA, without the need for rescue medication, in ...
HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; ULN, the upper limit of normal; TDF, tenofovir disoproxil fumarate; HBV, hepatitis B virus; anti-HBs, hepatitis B surface antibody.
CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract ...
SAN FRANCISCO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today ...
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both ...
Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data in chronic ...
– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...
Hosted on MSN
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, imdusiran and AB-101, at the European Association for the ...
Please provide your email address to receive an email when new articles are posted on . Chronic hepatitis B virus infection was significantly associated with an increased risk for intracerebral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback